妇科肿瘤PET/MR成像:正常解剖与良性病变同恶性肿瘤的鉴别要点
本文综述了PET/MR在妇科恶性肿瘤(子宫、宫颈、阴道及外阴癌)治疗前评估和监测中的应用,讨论了全身PET/MR的最佳协议和效用,重点阐述PET/MR相对于PET/CT的优势以及如何区分盆腔正常或良性妇科组织与癌症。
要点
- PET/MR结合MR高软组织分辨率和PET代谢信息,有助于更准确评估妇科肿瘤局部范围及远处转移。
- 阅片需注意区分正常或良性妇科组织的生理性摄取与肿瘤性摄取,避免假阳性。
- PET/MR在妇科恶性肿瘤评估中较PET/CT具有优势,但需掌握鉴别要点。
局限性
- 为综述,未提供原始研究数据或定量证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Positron emission tomography/magnetic resonance imaging (PET/MR) is used in the pre-treatment and surveillance settings to evaluate women with gynecologic malignancies, including uterine, cervical, vaginal and vulvar cancers. PET/MR combines the excellent spatial and contrast resolution of MR imaging for gynecologic tissues, with the functional metabolic information of PET, to aid in a more accurate assessment of local disease extent and distant metastatic disease. In this review, the optimal protocol and utility of whole-body PET/MR imaging in patients with gynecologic malignancies will be discussed, with an emphasis on the advantages of PET/MR over PET/CT and how to differentiate normal or benign gynecologic tissues from cancer in the pelvis.
引用
- Sadowski EA, Pirasteh A, McMillan AB, et al. PET/MR imaging in gynecologic cancer: tips for differentiating normal gynecologic anatomy and benign pathology versus cancer. Abdom Radiol (NY). 2021. PMID: 34687323. doi:10.1007/s00261-021-03264-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。